Zacks Research Estimates Biogen’s Q1 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) – Stock analysts at Zacks Research lifted their Q1 2026 earnings estimates for shares of Biogen in a research note issued to investors on Wednesday, October 22nd. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings of $3.47 per share for the quarter, up from their previous estimate of $3.45. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen’s Q2 2026 earnings at $3.79 EPS, Q4 2026 earnings at $3.94 EPS, FY2026 earnings at $14.87 EPS, Q2 2027 earnings at $3.96 EPS, Q3 2027 earnings at $4.01 EPS and FY2027 earnings at $15.88 EPS.

Several other research firms have also recently issued reports on BIIB. William Blair reiterated an “outperform” rating on shares of Biogen in a research report on Wednesday, September 24th. Morgan Stanley increased their target price on shares of Biogen from $144.00 to $149.00 and gave the company an “equal weight” rating in a report on Friday, October 10th. Citigroup restated a “neutral” rating on shares of Biogen in a report on Wednesday, September 24th. HC Wainwright raised their price target on Biogen from $187.00 to $194.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Finally, Truist Financial began coverage on shares of Biogen in a report on Monday, July 21st. They issued a “hold” rating and a $142.00 price target on the stock. Eleven investment analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $180.69.

Biogen Stock Performance

NASDAQ BIIB opened at $147.72 on Thursday. The stock has a market capitalization of $21.66 billion, a price-to-earnings ratio of 14.12, a PEG ratio of 1.16 and a beta of 0.13. The business’s 50 day moving average is $142.50 and its two-hundred day moving average is $131.81. Biogen has a 12-month low of $110.04 and a 12-month high of $187.58. The company has a current ratio of 2.50, a quick ratio of 1.79 and a debt-to-equity ratio of 0.36.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.93 by $1.54. The business had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.32 billion. Biogen had a net margin of 15.31% and a return on equity of 13.85%. The business’s revenue was up 7.3% compared to the same quarter last year. During the same period in the previous year, the business posted $5.28 earnings per share. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS.

Institutional Investors Weigh In On Biogen

Several institutional investors and hedge funds have recently modified their holdings of the stock. Generali Investments CEE investicni spolecnost a.s. increased its holdings in Biogen by 43.2% during the 2nd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 38,755 shares of the biotechnology company’s stock worth $4,867,000 after purchasing an additional 11,695 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Biogen by 6.5% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 416,960 shares of the biotechnology company’s stock worth $57,057,000 after buying an additional 25,464 shares during the last quarter. Asset Management One Co. Ltd. raised its holdings in Biogen by 5.5% in the first quarter. Asset Management One Co. Ltd. now owns 61,420 shares of the biotechnology company’s stock valued at $8,405,000 after acquiring an additional 3,194 shares in the last quarter. Nordea Investment Management AB boosted its stake in Biogen by 5.7% during the 2nd quarter. Nordea Investment Management AB now owns 125,935 shares of the biotechnology company’s stock valued at $15,810,000 after acquiring an additional 6,811 shares during the last quarter. Finally, Point72 Europe London LLP acquired a new position in Biogen during the 1st quarter worth $11,286,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Insider Activity at Biogen

In related news, insider Priya Singhal sold 517 shares of the company’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total value of $69,045.35. Following the completion of the transaction, the insider directly owned 5,772 shares in the company, valued at approximately $770,850.60. This represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.18% of the stock is currently owned by corporate insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.